- Home
- REVB vs ATCH Comparison
REVB vs ATCH Comparison
Compare REVB & ATCH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- REVB
- ATCH
- Stock Information
- Founded
- REVB 2020
- ATCH 2022
- Country
- REVB United States
- ATCH United States
- Employees
- REVB N/A
- ATCH N/A
- Industry
- REVB Biotechnology: Pharmaceutical Preparations
- ATCH
- Sector
- REVB Health Care
- ATCH
- Exchange
- REVB Nasdaq
- ATCH Nasdaq
- Market Cap
- REVB 2.3M
- ATCH 2.5M
- IPO Year
- REVB N/A
- ATCH N/A
- Fundamental
- Price
- REVB $4.31
- ATCH $2.35
- Analyst Decision
- REVB
- ATCH
- Analyst Count
- REVB 0
- ATCH 0
- Target Price
- REVB N/A
- ATCH N/A
- AVG Volume (30 Days)
- REVB 175.9K
- ATCH 250.1K
- Earning Date
- REVB 03-21-2025
- ATCH 02-19-2025
- Dividend Yield
- REVB N/A
- ATCH N/A
- EPS Growth
- REVB N/A
- ATCH N/A
- EPS
- REVB N/A
- ATCH 2.67
- Revenue
- REVB N/A
- ATCH N/A
- Revenue This Year
- REVB N/A
- ATCH N/A
- Revenue Next Year
- REVB N/A
- ATCH N/A
- P/E Ratio
- REVB N/A
- ATCH $0.88
- Revenue Growth
- REVB N/A
- ATCH N/A
- 52 Week Low
- REVB $3.34
- ATCH $1.73
- 52 Week High
- REVB $69.44
- ATCH $209.40
- Technical
- Relative Strength Index (RSI)
- REVB 40.86
- ATCH 23.48
- Support Level
- REVB $3.80
- ATCH $1.73
- Resistance Level
- REVB $4.54
- ATCH $2.40
- Average True Range (ATR)
- REVB 0.37
- ATCH 0.60
- MACD
- REVB 0.18
- ATCH 0.07
- Stochastic Oscillator
- REVB 68.13
- ATCH 20.53
About REVB Revelation Biosciences Inc.
Revelation Biosciences Inc is a clinical-stage life sciences company focused on the development of therapies for the prevention and treatment of disease using trained immunity. It is developing a pipeline of potential high-value products based on Gemini. Gemini is Revelation's proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD) an established TLR4 agonist that can stimulate the human body's innate immune response to prevent and treat disease. The product candidates are developed are based on Gemini formulation of PHAD. Gemini based programs consist of: Gemini-SSI developed for the prevention of surgical site infection (SSI); Gemini-AKI developed for the prevention of acute kidney injury (AKI); and Gemini-CKD for the treatment of chronic kidney disease (CKD).
About ATCH AtlasClear Holdings Inc. Common Stock
AtlasClear Holdings Inc is a fintech company. Its goal is to build a cutting-edge technology-enabled financial services firm that would create a more efficient platform for trading, clearing, settlement, and banking of evolving and innovative financial products with a focus on financial services firms. It is a fintech-driven business-to-business platform that expects to power innovation in fintech, investing, and trading. The company believes it is positioned to provide a modern, mission-critical suite of solutions to its clients, enabling them to reduce their transaction costs and compete more effectively in their businesses.